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Abstract.  Using immunohistochemical  methods, we 
have investigated the role of transforming growth 
factor-13 (TGF-13) in the development of the mouse em- 
bryo. For detection of TGF-13 in  ll-18-d-old embryos, 
we have used a polyclonal antibody specific for TGF-13 
type 1 and the peroxidase-antiperoxidase technique. 
Staining of TGF-fl is closely associated with mesen- 
chyme per se or with tissues derived from mesen- 
chyme, such as connective tissue, cartilage,  and bone. 
TGF-13 is conspicuous in tissues derived from neural 
crest mesenchyme,  such as the palate,  larynx,  facial 
mesenchyme, nasal  sinuses,  meninges,  and teeth. 
Staining  of all of these tissues is greatest during 
periods of morphogenesis.  In many instances,  intense 
staining is seen in mesenchyme when critical interac- 
tions with adjacent epithelium occur, as in the devel- 
opment of hair follicles, teeth, and the submandibular 
gland.  Marked staining  is also seen when remodeling 
of mesenchyme or mesoderm occurs, as during  forma- 
tion of digits from limb buds, formation of the palate, 
and formation of the heart valves. The presence of 
TGF-13 is often coupled with pronounced angiogenic 
activity. The histochemical results are discussed in 
terms of the known biochemical actions of TGF-13, es- 
pecially its ability to control both synthesis and degra- 
dation of both structural  and adhesion molecules of 
the extracellular matrix. 
T 
RANSFORMING growth  factor-13 (TGF-13),  ~ first dis- 
covered in an assay based on its ability to transform fi- 
broblasts phenotypically in culture,  by now has been 
shown to have profound effects on nearly all cell types, in- 
fluencing either their proliferation,  differentiation,  or other 
aspects of their function (for reviews, see Roberts and Sporn, 
1987; Sporn et al., 1986, 1987). The amino acid sequence of 
TGF-13 is totally conserved among human, bovine, and por- 
cine species (Derynck et al., 1985; Derynck and P,  hee, 1987; 
Van Obberghen et al., 1987), indicating that the functions it 
controls may be critical for the organism.  Recently, a second 
form of TGF-13, with identical  biological activity in many 
cells, has been described (for a review, see Massagu6,  1987); 
the partial amino acid sequence of this peptide, called TGF- 
132,  is  also highly  conserved in  humans,  cows,  and  pigs 
(Wrann et al.,  1987; Ikeda et al.,  1987; Seyedin et al.,  1987; 
Cheifetz  et al.,  1987). 
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1. Abbreviations  used in this paper: TGF-13, transforming growth factor-t3; 
SPARC,  secreted protein, acidic, rich in cysteine. 
The high concentrations  of TGF-13 found in platelets  (As- 
soian et al.,  1983) and in bone (Seyedin et al.,  1985, 1986) 
suggest that it might have a significant role in repair of tissue 
damage  (Sporn  et  al.,  1983) and  in  bone  formation  and 
remodeling  (Centrella  et al., 1987; Robey et al., 1987; Pfeil- 
schifter and Mundy,  1987). Indeed, subcutaneous injection 
of IGF-13 into  newborn  mice produces a  granulation  re- 
sponse (formation  of new blood vessels and connective tis- 
sue) similar to that seen in a healing wound (Roberts et al., 
1986). Studies in vitro have shown that TGF-13 controls for- 
mation of connective  tissue proteins  such  as collagen  and 
fibronectin  in various  mesenchymal  cells (Ignotz and Mas- 
sagu6, 1986; Roberts et al., 1986; Varga and Jimenez, 1986; 
Fine and Goldstein,  1987; Ignotz et al., 1987). In this respect, 
TGF-I~ controls two separate processes: (a) synthesis,  which 
TGF-13 increases by enhancing  the activity of the promoters 
for the fibronectin (Bourgeois,  S., personal communication) 
and type I collagen genes (Rossi et al., 1988), and (b) degra- 
dation, which TGF-13 blocks, both by decreasing secretion of 
proteases and by increasing  secretion of protease inhibitors 
(Chiang and Nilsen-Hamilton,  1986; Laiho et al., 1986; Ed- 
wards et al., 1987; Lund et al., 1987). The net result of these 
effects of TGF-13 on the synthesis and degradation  of matrix 
proteins  is a marked enhancement  of their accumulation. 
It has often been proposed that cellular and biochemical 
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during tissue repair in the adult; angiogenesis, and the syn- 
thesis and degradation of matrix proteins such as collagen 
and fibronectin, are all critical processes in embryogenesis 
(Newgreen and Thiery, 1980; Hay, 1981; Rovasio et al., 1983; 
Icardo and Manasek, 1984). The remarkable conservation of 
TGF-13 sequences between species,  its ability to modulate 
cellular differentiation and cellular function, together with 
its specific effects on matrix protein formation, on chemo- 
taxis of cells (Postlethwaite et al.,  1987; Wahl et al.,  1987), 
and  on  angiogenesis  (Roberts et  al.,  1986;  Madri  et al., 
1988),  all strongly suggest that this peptide plays a funda- 
mental  role in embryogenesis.  Two other members of the 
TGF-15 family of peptides,  Miillerian  inhibitory  substance 
(Cate  et al.,  1986)  and  the product  of the  decapentaple- 
gic gene complex in Drosophila (Padgett et al.,  1987) have 
already  been  implicated  in  embryonic  remodeling  of the 
developing  male  reproductive  system of mammals  and  in 
dorsal-ventral  patterning  in  the  fly  embryo,  respectively. 
TGF-13-1ike activity has been reported in extracts of mouse 
embryos (Proper et al.,  1982;  Hill et al.,  1986),  and im- 
munohistochemical staining has demonstrated the presence 
of TGFq3 in bone, liver, and thymus of 6-mo bovine fetuses 
(Ellingsworth et al., 1986). However, the intrinsic physiolog- 
ical  role of this  peptide  in the developing embryo is  still 
unknown. 
The present studies were therefore undertaken to obtain fur- 
ther information about the role of TGF-13 at different stages 
of the development of the mouse embryo, beginning at 11 d 
of gestation; analysis of earlier embryos is clearly also re- 
quired and will be the subject of future studies, focusing not 
only on rodent but also on early chick embryos. Here, we 
present data that suggest that TGF-13 has an important role 
in many embryonic tissues, particularly in those of mesoder- 
mal and neural crest origin,  at specific times when critical 
morphogenetic and histogenetic events occur. We have used 
Northern RNA blot and immunohistochemical  methods for 
these  studies  and  have  developed  improved  methods  for 
demonstrating  the  specificity of the immunohistochemical 
staining of TGF-[~. These studies provide new insights into 
tissue  and  organ-specific  sites  of TGF-13 action;  both the 
spatial and temporal patterns of TGF-13 expression provide 
clues to its specific effects on the developmental programs in 
target  tissues.  In  this  article,  we present  an  overview of 
our results in the embryo as a whole; more detailed investiga- 
tions of the specific immunohistochemical  staining patterns 
of TGF-I3 in specialized tissues will be the subject of future 
communications. 
Materials and Methods 
Extraction of  RNA  from Mouse  Embryos 
RNA was prepared from Swiss-Webster mouse embryos at different stages 
of development; at early stages (days 8-10) the entire conceptus including 
both embryonic and extraembryonic tissue was removed from the uterine 
wall,  whereas  at later stages,  the embryo proper was  dissected  free of 
placenta and extraembryonic tissues. Embryos were quick frozen in liquid 
nitrogen. Total RNA was isolated from ,x,1 g of embryos at each stage by 
the method of Auffray and Rougeon,  1980 (extraction in 3  M  LiCI, 6  M 
urea, 0.1% SDS, 0.01 M NaOAc, pH 5, 100 ~tg/ml heparin); poly(A)  + RNA 
was then prepared by one cycle of chromatography on oligo(dT)-cellulose. 
1 lag of poly(A)  + RNA was electrophoresed in 1.2% agarose gels and elec- 
troblotted onto nitrocellulose. Blots were hybridized with a nick-translated 
murine cDNA probe (Derynck et al.,  1986).  Blots were washed at 60~  in 
0.1  ￿  SSC, 0.1%  SDS. 
Antibodies 
Polyclonal antibodies to TGF-131 were made in rabbits to a synthetic peptide 
corresponding to the amino-terminal 30 amino acids of TGF-131 as described 
by Ellingsv~rth et al. (1986). These antibodies specifically detect TGF-131, and 
do not recognize "IGF-132. IgG fractions, prepared from these antisera by 
passage over protein A-Sepharose (Elliugsworth et al.,  1986), were used for 
all experiments reported here. For control experiments, we removed TGF- 
[3-specific antibodies by incubating aliquots of IgG (250 gl) with ,',,200  gl 
of Sepharose (agarose gel, Pharmacia Fine Chemicals, Piscataway,  NJ), to 
which TGF-[II had been coupled as described previously (Florini et al., 
1986); an equivalent aliquot of the IgG was also incubated with uncoupled 
Affi-gel 10 (a derivatized cross-linked agarose gel, Bio-Rad Laboratories, 
Richmond, CA) as a positive control. After an overnight incubation at 4~ 
the coupled Sepharose or the Afli-gel was removed by centrifugation. The 
supernatants were tested for their abilities to recognize 'I'GF-13 in an enzyme- 
linked immunosorbent assay (Flanders et al.,  1987) to evaluate the com- 
pleteness of removal of TGF-13-specific antibodies; the IgG treated with 
uncoupled agarose had a titer of 1.'750 in the assay, whereas there was no 
detectable reactivity of the IgG that had been treated with agarose coupled 
to TGF-[L 
Immunohistochemical Staining 
The distribution of TGF-13 was evaluated by immunohistochemical staining 
of sagittal sections prepared from whole mouse embryos of 11, 13, 15, and 
18 d of gestation. Embryos were fixed in Bouin solution (0.9% picric acid, 
9%  [vol/vol] formaldehyde, 5% acetic acid). After dehydration through a 
graded series of ethanol solutions, the embryos were embedded in paraffin. 
Sections 5 em thick were deparaflinized, stained with Harris hematoxylin, 
and subjected to immunohistochemical staining using the following sched- 
ule: (a) blocking of endogenous pemxidase with 0.3% hydrogen peroxide 
in methanol (30 min); (b) treatment with  1 mg/ml hyaluronidase (Sigma 
Chemical Co., St. Louis, MO), buffered to pH 5.5 with 0.1 M sodium ace- 
tate in 0.15 M NaCI (30 min); (c) blocking of nonspecific protein binding 
with 10% goat serum (45 min); (cO incubation with 0.1 mg/ml anti-TGF-[3 
(at 4~  overnight); (e) incubation with afffinity-purified  goat anti-rabbit IgG 
diluted 1:40 in buffer (1 h); (f) incubation with rabbit peroxidase-antiperoxi- 
dase diluted  1:100 in buffer (1  h); and (g) treatment with 0.5 mg/ml di- 
aminobenzidine (Sigma Chemical Co.) in 0.05 M Tris-buffered saline (0.05 
M Tris buffer, pH 7.2, 0.15 M  NaCI) containing 0.1%  H202 (5 min). The 
buffer solution used for rinsing between each step consisted of 0.01 M Tris- 
buffered saline, 0.1%  normal goat serum, and merthiolate in a dilution of 
1:10,000. For antibody dilution, the following solution was used: 0.01 M 
Tris-buffered saline,  1%  normal goat serum,  and merthiolate diluted as 
above. Controls were done either by (a) replacing the anti-TGF-[3 rabbit IgG 
by normal rabbit IgG or bovine serum albumin or (b) using the antigen- 
depleted lgG preparation described above.  Normal goat serum,  afffinity- 
purified goat anti-rabbit IgG, and peroxidase-antiperoxidase were obtained 
from Cooper Biomedical, Inc., Malvern,  PA. 
Results 
Expression of  mRNA for TGF-~ in Mouse  Embryos 
For our initial investigation of TGF-13 during development, 
expression of TGF-t31 mRNA in mouse embryos of different 
gestational age was examined by Northern blot analysis. As 
shown in Fig. 1, relatively high levels of'l'GF-13 mRNA were 
detected in poly(A)  + RNA prepared from embryos ranging 
from 8 to 18 d of age. This continuous high expression is in 
marked contrast to that found for TGF-a, which is expressed 
primarily in early embryos (Lee et al., 1985). To address the 
roles of TGF-13 in  embryogenesis,  and  to identify  tissue- 
specific and cell-specific developmentally regulated sites of 
TGF-[~ action,  an immunohistochemical  analysis of TGF-I3 
localization in sections of whole, fixed mouse embryos was 
undertaken,  using an antibody raised against the NH2-ter- 
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ages was electrophoresed on agarose gels, blotted, and hybridized 
to a murine TGF-131 cDNA probe, mRNA at days 8-10 of develop- 
ment was prepared from the entire conceptus, whereas mRNA from 
all other embryos was prepared from the embryo proper. 
minal 30 amino acids of the mature TGF-131 molecule (EI- 
lingsworth et al.,  1986). 
Specificity of Staining 
An IgG fraction from normal rabbit serum was used as the 
primary control for most studies. For more complete demon- 
stration of the specificity of the staining, we first attempted 
to block the staining by preincubating the anti-TGF-13 IgG 
with a  solution of the peptide against which it was raised. 
While this procedure generally resulted in a substantial de- 
crease in the intensity of the staining, it did not completely 
abolish the staining. Inasmuch as the peptide 1-30 of TGF-I3 
has limited solubility at neutral pH, it is possible that the an- 
tibody was not completely saturated with peptide. Moreover, 
the ligand (either peptide  1-30 or TGF-13 itself) bound to a 
solid support has higher affinity for the antibody than ligand 
in solution (not shown). For these reasons we adopted an al- 
ternative approach to demonstrate specificity: we removed 
the TGF-13-specific antibodies from the IgG by preincubat- 
ing it with Sepharose (agarose gel) to which TGF-13  had been 
coupled. This preincubated, depleted IgG preparation showed 
no reactivity toward TGF-13  or peptide 1-30 in an ELISA as- 
say (see Materials and Methods). In these experiments, anti- 
TGF-13 IgG preincubated with agarose to which no ligand 
had been coupled was used as the positive control. Fig.  2 
shows an area of the tail of a  15-d embryo stained with anti- 
TGF-13 IgG that was preincubated with either control agarose 
(Fig. 2 A) or with agarose to which TGF-I~ had been coupled 
(Fig. 2 B). The TGF-~-specific staining is localized in the 
connective tissue sheath separating developing muscles from 
the subdermal mesenchyme and also in fibroblasts separat- 
ing individual groups of  myotubes. No staining was observed 
when the depleted IgG was used (Fig. 2 B), thus demonstrat- 
Figure 2. Parasagittal section through the tail of a 15-d embryo. (A) Antibodies to TGF-I~  incubated with uncoupled agarose (see Materials 
and Methods) stain connective tissue sheaths of muscle; (B) an equivalent aliquot of antibody incubated with agarose to which TGF-13 
had been coupled gave no staining. Dilution of the anti-TGF-I~ IgG preparation was 1:390. Bar, 100 ~tm. 
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is seen in many tissues in A, and essentially nowhere in B. Erythrocytes within the heart and liver are peroxidase-positive in both figures. 
￿  Bar,  100 Ixm. 
ing  specific TGF-13 immunoreactivity.  Although  we  have 
shown that immunoreactive staining is abolished by pread- 
sorbing immune IgG with TGF-13, at present we do not know 
which specific epitope or set of epitopes on TGF-t3 is recog- 
nized by this IgG preparation, nor do we know the molecular 
form or physical state of the epitope. Thus, it is possible that 
some of the staining we have observed is the result of  the anti- 
body  interacting  with  TGF-13 precursor molecules,  rather 
than the mature molecular species, although we can exclude 
the possibility of staining of type 2 TGF-13 (Ellingsworth et 
al.,  1986). 
Effect of  Fixative 
The distribution pattern of  TGF-I3 observed in the developing 
embryo was found to be dependent on the fixative  used. Fixa- 
tion with p-formaldehyde at neutral pH resulted in staining 
of cartilage only. This pattern was most markedly seen in 
embryos of days 13 and 15, after the cartilaginous skeleton 
has been formed (not shown). In contrast, Bouin fixation, at 
pH 2, also resulted in staining of cartilage, but, in addition, 
resulted in strong staining of the mesenchyme in many areas 
of the embryo (Fig. 3 A); TGF-13 staining was especially in- 
tense in regions of  active histogenesis and organogenesis. All 
of  these areas were devoid of  reaction in sections stained with 
normal rabbit IgG (Fig. 3 B). Because Bouin fixation was 
more useful, it was used exclusively for the rest of the study 
of the developmental patterns of TGF-[~ expression reported 
here. 
Immunohistochemical Localization  of TGF-~ 
A  general  conclusion  is  that  TGF-[3  is  often  closely  as- 
sociated with mesenchyme per se or with tissues that are de- 
rived from mesenchyme, such as  connective tissue,  carti- 
lage, and bone. TGF-13 is particularly conspicuous in tissues 
derived from the neural crest mesenchyme as seen, for exam- 
ple, in the developing palate, larynx, facial mesenchyme, na- 
sal sinuses, meninges, and teeth (Figs. 3 A, 5, 8, 10, and 11). 
The expression of TGF-13 in all of these tissues is greatest 
during periods of morphogenesis. Often, the staining pattern 
of TGF-13 in connective tissue outlines demarcations both 
within and between individual tissues, such as in the connec- 
tive tissue sheaths separating groups of myotubes in develop- 
Figure 4. TGF-I~  in mesenchymal connective tissue ofa 15-d  embryo. (A) Muscle. TGF-13  is present in the cytoplasm of fibroblasts (arrows) 
that separate individual myotubes. Fascia (F) between two muscles shows intense staining for TGF-13. x400. (B) Submandibular gland. 
TGF-13 is stained in the connective tissue surrounding the glandular epithelium,  x150. (C) Intestine. "I'GF-t~  is present in the submucosa. 
x250. (D) Hindfoot. TGF-13  staining is localized preferentially in the capillary-rich, subdermal mesenchyme (arrow),  in fascia surrounding 
developing muscles, and in joints between the cartilaginous bones of the digits.  ￿  Bar,  t00 txm. 
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tween different tissues, such as between muscle and dermis 
(Fig. 2 A). In many instances, such as in the development of 
hair follicles (see Fig. 10), and teeth (see Fig. U), expression 
of TGF-13 is  found in  tissues  in  which critical mesenchy- 
mal-epithelial interactions occur (see Hay,  1981). Further 
examples are seen in the submandibular gland,  where in- 
tense TGF-13 staining was seen in underlying mesenchyme 
(also of neural crest origin) but not in glandular epithelial 
cells (Fig. 4 B) and in the developing intestine, where stain- 
ing was seen only in the submucosa, but not in mucosal epi- 
thelial cells (Fig. 4  C). Particularly intense TGF-13 staining 
also can be seen when remodelling of mesenchyme or meso- 
derm occurs, as during formation of digits from limb buds 
(Fig. 4 D), formation of the palate (Fig. 5 A), and formation 
of the heart valves (see Fig. 9). In many of these situations, 
the presence of TGF-13 was coupled with marked angiogenic 
activity, as seen, for example, in the marginal blood sinuses 
of the limbs between days 13 and 15 (Fig. 4 D). Specific fea- 
tures of the staining patterns of TGF-I~ in a variety of tissues 
and their developmental sequences will be discussed in great- 
er detail below. 
Notochord.  Between days 11 and 15, the notochord (not il- 
lustrated) shows two distinct areas of staining for TGF-13: (a) 
the cell-free sheet of collagen fibers surrounding the noto- 
chord and (b) single cells or small groups of cells in the cen- 
tral  part of the notochord. The distribution of these cells 
coincided with the future localization of intervertebral disks. 
Somites, Sclerotome,  and Early Vertebrae. Because the 
anterior axial skeleton develops earlier than the caudal skele- 
ton, it was possible to evaluate the entire developmental pat- 
tern of TGF-13  expression by examination of different regions 
of the skeleton in single embryos. At day 11, the caudal part 
of the axial skeleton is still composed of somites. The distri- 
bution of TGF-I$ was homogeneous throughout each caudal 
somite; numerous individual cells with cytoplasmic localiza- 
tion of the peptide were scattered throughout each segment 
(Fig. 6 A). Between days 11 and  13, after the somites have 
differentiated into  sclerotome,  myotome, and  dermatome, 
only the sclerotome and dermatome stained positively for 
Figure 5.  Staining of TGF-I~ in craniofa- 
cial and cervical structures. (A) Parasagit- 
tal  section  through  the  head  of a  15-d 
embryo. TGF-13 is found in the dermis, 
connective tissue of the tongue (T), and 
the stellate reticulum of  the developing in- 
cisor (arrow). Intense staining is present 
in various tissues of neural crest origin, 
such as the cartilage of facial bones, mes- 
enchyme  of  developing  nasal conchae 
(N), palate (P), and papilla of incisor. 
x24.  (B) Larynx. Section through  the 
larynx of a  15-d embryo. Laryngeal and 
tracheal cartilages (x) as well as the laryn- 
geal ventricles are forming at this time. 
Intense staining for TGF-I~  is seen in mes- 
enchyme between tracheal cartilage and 
epithelium (arrow), in the sternum (S), 
and in the larynx (L). Bar, 100 Ixm. 
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phogenesis of vertebrae.  (A) Somites in 
the tail region of an ll-12-d embryo. TGF- 
13 is present in the cytoplasm of individual 
cells that are distributed evenly through- 
out each somite. Epidermis consisting of 
a  single cell layer is marked by arrows. 
(B) Sclerotomes in the caudal spinal col- 
umn  of a  13-d embryo. TGF-I~ is local- 
ized in the anterior (arrows) and posterior 
(arrowheads)  regions of individual sclero- 
tomes.  The  staining pattern demarcates 
the formation of future vertebrae. Menin- 
ges (x) covering the spinal cord (S) are in- 
tensely stained.  (C) Definitive vertebrae 
in the rostral spinal column of a 13-d em- 
bryo.  Areas  of vertebra  formation  (ar- 
rows),  distinguished by low cell density 
(indicating the beginning of chondrogene- 
sis), show staining for TGF-13. In contrast, 
the areas representing the perichordal  discs 
(x) do not stain. The meninges covering 
the spinal cord (S) are strongly positive 
for TGF-13, as seen in B. Bar,  100 I.tm. 
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vertebrae from individual  sclerotomal  segments  was  pre- 
ceded by a change in TGF-13  distribution, namely, the stain- 
ing became intensified in the posterior half of one segment 
and  in  the  anterior  half  of the  following  segment,  thus 
defining the future vertebral centrum (Fig. 6 B). Soon after 
these two areas fused to form the body of a single vertebra 
(as first described by Remak, 1855), they became character- 
ized by low tissue density, indicating the beginning of chon- 
drification (Fig. 6  C).  Areas of chondrification, as well as 
the resulting cartilage and, later on, calcified cartilage and 
ossification centers of individual bones, stained positive for 
TGF-13 (Fig.  7 A). 
Bones.  In long bones, endochondral ossification starts by 
invasion of capillaries into the perichondrium, thus trigger- 
ing  the  transformation  of the  perichondrium  into  a  peri- 
osteum. In these areas, narrow bands of osteoblasts adjacent 
to the cartilaginous bone form the primary ossification cen- 
ters.  In  such  areas  of active  capillary  growth  and  bone 
matrix formation, as well as in the cytoplasm of the osteo- 
blasts per se (days 15 and 18), intense staining for TGF-~ was 
observed (Fig.  7 A).  Areas of joint formation, such as the 
articulations  between  vertebrae and  between  long  bones, 
also stained positive for TGF-I~ (Fig. 4 D). At day 15, strong 
TGF-13 staining was found in areas of intramembranous ossi- 
fication of flat bones, as in the calvarium (Fig. 7 B). 
Meninges.  A  transverse  section  of the  head  at  day  13 
clearly outlines the presence of TGF-13 in the meninges of the 
brain  (Fig.  8 A).  In the mouse,  the three structures (dura 
mater, arachnoid, and pia mater) comprising the meninges 
differentiate between days 11 and 15 of gestation. During de- 
velopment of the meninges, two zones may be distinguished: 
an outer one of condensation of mesenchyme, which gives 
rise to the periosteum, dura mater, and membranous arach- 
noid, and an inner zone, which becomes the pia mater. The 
developmental pattern of TGF-13 staining reflects sequential 
differences in the development of these two zones. At day 11, 
TGF-13 staining was seen mainly in a single layer of elongated 
fibroblasts overlying neural tissue (Fig. 8 B). These were the 
first recognizable cells of the developing meninges. As dif- 
Figure 7.  Staining of TGF-13 during both 
endochondral and intramembraneous os- 
sification. (A) Section through the rib of 
an 18-d embryo with areas of calcification 
that are  positive for TGF-13. x150. (B) 
Calvarium of a 15-d embryo with intense 
staining of membranous bone. Note also 
the narrow band of staining in the dermis 
(arrow). Bar, 100 Ixm. 
The Journal  of Cell Biology,  Volume 105, 1987  2868 Figure 8. Staining of TGF-13 in developing  meninges. (A) Low-power  transverse section through the head ofa 13-d embryo. The meninges 
stain strongly. ￿  (B) Parasagittal section through the parietal lobe of a lid embryo. A single layer of elongated TGF-13-positive cells 
(arrows)  indicates the earliest stage in the development  of  the meninges  of the brain (B). x400. (C) Parasagittal  section through the frontal 
lobe of an ll-d embryo. In early stages of development of the arachnoidal spaces, staining is localized in the cytoplasm of the arachnoid 
endothelium and in cells of the pia mater (arrows). Arachnoidal spaces are filled with immature, nucleated red blood cells.  ￿  (D) 
Section through the meninges of a 15-d embryo. Late stages of arachnoidal development are characterized by reduced TGF-13 staining in 
the arachnoidal endothelium and enhanced staining in cells of the pia mater (arrows).  Neural tissue in the adjacent brain also shows  diffuse 
staining for TGF-t3 at this time. x400. Bar, 100 ~tm. 
ferentiation of the netlike structure of the arachnoid pro- 
ceeded from this cell layer, staining for TGF-13 in this area 
remained intense. At this same time, numerous cells of the 
underlying pia mater were still negative for TGF-13 but began 
to stain positively between days 11 and 13 of gestation (Fig. 
8 C). By day 15, differentiation of the arachnoid was com- 
plete in many areas, and arachnoidal staining was very weak, 
whereas in contrast, the pia mater now stained strongly posi- 
tive for TGF-13 (Fig. 8 D). In addition, marked staining of 
the meninges surrounding the spinal cord was seen between 
days 11  and 15 of gestation (Fig. 6, B and C). 
Cushion Tissue of the Heart. The mesenchymal cushion 
tissue of  the heart stained strongly positive for TGF-13 at days 
11 and 13 of  gestation (Fig. 9, A and B). Neither the overlying 
endocardium, thought to be the origin of the cushion tissue, 
nor  the  developing myocardium showed any  staining  for 
TGF-13. The period between days 10 and 14 of gestation is of 
major importance in the development of the heart inasmuch 
as both cytodifferentiation  and remodeling occur, especially 
in  cushion  tissue  and  adjacent  areas.  The  progressive 
changes that occur include fusion of the endocardial cush- 
ions (day 11), and development of the septum primum (day 
11.5), the atrioventricular valves (day  13), and  semilunar 
valves (day 14). TGF-13 appears to be involved in all these 
events. At day 15, TGF-13 still stained strongly in the mesen- 
chyme of the valves (Fig. 9,  C and D). 
Hair Follicles.  The developmentally dependent staining 
pattern of  TGF-13 during maturation of  hair follicles indicates 
that it might play a role, either direct or indirect, in mesen- 
chymal-epithelial interactions involved in their differentia- 
tion. This can be seen particularly during the development 
of the hair follicles of the snout, which form the vibrissae 
(sensory whiskers), as shown in Figs. 5 A and 113. The mesen- 
chyme underlying the epidermis stained weakly for TGF-13 
before the actual appearance of  the hair germ cells (early hair 
follicle). During this time, around day 11, numerous capil- 
laries were present in the mesenchyme (Fig. 10 A). As devel- 
opment of the hair follicles continued, the staining of'l'GF-13 
in the mesenchyme increased in intensity (day 13, Fig. 10 B; 
day 15, Figs. 5 A and 10 C); however,  this staining disap- 
peared after completion of hair follicle formation (day 18, 
Fig.  10 D).  The staining pattern of TGF-I3 in the mesen- 
chyme surrounding the developing follicle was always cor- 
related with hair development in the epithelial cells of  the fol- 
Heine et al,  Transforming Growth Factor-~ in Mouse Embryo  2869 Figure 9.  Staining of TGF-13 in the cushion tissue of the heart.  (A) Section through the heart of an  ll-12-d embryo. TGF-13 is localized 
in the cushion tissue (arrows) of the developing valves. Liver (L) and spinal column (SC) are recognizable,  x86. (B) Enlargement of 
Fig. 7 A. TGF-13  is localized in the cytoplasm of ceils of the cushion tissue. Adjacent multilayered endocardium (X) is negative for TGF-13. 
x150.  (C) Section through the heart of a  15-d embryo. TGF-13 is present in the atrioventricular valve (arrow). Note also the staining for 
TGF-13 in the mesenchyme of the trachea (T).  x36. (D) Enlargement of Fig. 7 C. Particularly intense TGF-15 staining is present in the 
cytoplasm of cells comprising the connective tissue of the atrioventricular valve,  x150.  Bar,  100 ttm. 
The Journal of Cell Biology,  Volume 105, 1987  2870 Figure 10 Staining of TGF-13 in mesenchyme associated with development of hair follicles of the snout. (A) Parasagittal section through 
the mandible of an ll-d embryo. The earliest indication of the development of vibrissae is indicated by a light staining for 'I'GF-13  in the 
mesenchyme of the dermis and by the vascularization of the same area (arrows). x150.  (B) Parasagittal section through the mandible of 
a  13-d embryo. Intense staining for TGF-I3 in the mesenchyme underlying the epidermis. Local aggregation of epidermal cells (arrows) 
indicates early hair follicle formation. L-lip furrow band.  x150.  (C) Parasagittal section through the mandible of a  15-d embryo. Intense 
staining of TGF-I3 is present in the mesenchyme of the dermis surrounding the developing hair follicles. The vascularization of this area 
is pronounced (arrows). ￿  (D) Parasagittal section through the mandible of an 18-d embryo showing the lack of ]'GF-I3 staining in 
mesenchyme at a time when the development of the vibrissae is near completion.  ￿  Bar,  100 [tm. licle; thus, as formation of the vibrissae preceded that of the 
body hair, staining of TGF-13 in the mesenchyme around the 
developing vibrissae  preceded that in mesenchyme in re- 
gions of presumptive hair follicles of body hair (not shown). 
Little, if any, staining of any follicles themselves was seen 
at any time. Furthermore, in those areas of skin that do not 
participate in hair formation, such as the tail region, mesen- 
chyme underlying epithelium did not stain for TGF-13. 
Teeth.  Development of the teeth, especially the incisors, 
like that of the vibrissae discussed above, is another instance 
in which TGF-fl may influence mesenchymal-epithelial in- 
teractions and may also induce mesenchymal cells to synthe- 
size a specific set of matrix proteins. At day 11, faint staining 
for TGF-13 was  observed  in areas  of neural  crest-derived 
mesenchyme that underlie the epithelial tooth buds. During 
the cap stage of tooth development (day 13), faint staining 
was found in the mesenchyme adjacent to the forming tooth 
(Fig. 11 A). In the subsequent bell stage of development (day 
15), TGF-13 staining became locally pronounced in cells of 
neural crest origin, as they were incorporated into the primi- 
tive dental papilla. The deep staining of the mesenchyme of 
the papilla at this stage suggests a high concentration of TGF-13 
(see Figs. 5 A and 11 B). 
During the course of epidermal invagination into the un- 
derlying mesenchyme (to  form the bell-shaped tooth), an 
undifferentiated  mesenchyme of epithelial origin, the stellate 
reticulum, accumulates between the outer and inner dental 
epithelium. This reticulum also reacted positively with anti- 
bodies to TGF-13 (Fig. 11 B). Likewise, positive staining for 
TGF-13 was observed in tissue surrounding the capillaries 
that infiltrate the developing tooth under the outer dental epi- 
thelium. At day 18 of gestation, TGF-13 was still detectable 
in the less developed teeth (not shown). It is of interest that 
biochemical studies have recently shown high levels of ex- 
pression  of mRNA  for  TGF-fl  in  cells  derived  from the 
ameloblastic layer of fetal bovine teeth (Robey et al.,  1987). 
Muscle. Sections of the developing muscle taken between 
days 13 and 18 did not show TGF-13-specific staining in either 
myogenic cells or myotubes, per se.  However,  during the 
same period, loose connective tissue sheaths surrounding the 
Figure 11. Staining  of TGF-I~ in the devel- 
oping incisors of the 13-15-d embryo. (A) 
Lower incisor (13 d) showing  faint staining 
of the mesenchyme  adjacent to the incisor 
primordium (arrow). (*) Lip furrow band. 
(B) Upper incisor (15 d) showing strong 
staining for TGF-13 in the papilla (arrow) 
and stellate reticulum (*). Note also the 
intense staining in the nasal sinuses (N). 
Bar, 100 I.tm. 
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groups of myotubes within the muscle proper, stained posi- 
tive for TGF-13 (Figs. 2 A and 4 A). This pattern was espe- 
cially pronounced in the tongue (musculus verticalis lin- 
guae), in which individual myotubes alternated with deeply 
stained narrow strands of connective tissue. At day 18, after 
striated muscle fibers have been formed, the fascia surround- 
ing many muscles continued to stain positive for TGF-fl. 
Discussion 
Results obtained in the present study clearly indicate that 
TGF-13 is expressed in a unique pattern, both spatially and 
temporally, in the developing mouse embryo. This highly 
specific pattern of histochemical staining of TGF-13 in the 
embryo appears to correlate with specific morphogenetic and 
histogenetic events, particularly those involving cells and tis- 
sues of mesenchymal or mesodermal origin. In accordance 
with our observations in the mouse,  it has recently been 
shown that TGF-13 can exert a potent inductive effect on the 
formation of mesoderm from ectoderm in amphibian em- 
bryos, prior to gastrulation (Kimelman and Kirschner, 1987). 
Because the bulk of the vertebrate organism is composed of 
mesodermal cells and tissues, it is apparent that TGF-I~ par- 
ticipates in some fundamental way in the basic architecture 
and organization of almost the entire developing embryo. 
Particularly striking in this respect is the manner in which 
TGFq3 contributes to the segmentation of the axial skeleton, 
a  fundamental characteristic of all vertebrates. It has been 
known for more than a century (Remak, 1855) that each ver- 
tebral body is derived from sclerotomal mesenchyme origi- 
nating from two somites (the posterior part of one somite and 
the anterior part of the somite immediately caudal to it), and 
the participation of TGF-13 in this process can be seen in Fig. 
6, A-C. Furthermore, not only does TGF-13 appear to have 
some organizational role in the original morphogenesis of a 
vertebral body, but it then has some additional role in its sub- 
sequent chondrification and ossification. The ultimate for- 
mation of a definitive structure such as a vertebra involves 
a set of steps which, at the cellular level, consist of a series 
of chemotactic, proliferative, and differentiative events, and 
which, at the tissue level, consist of a sequence of modeling 
and remodeling events, until the final mature structure is 
formed (Bellairs et al.,  1986). 
Although one cannot prove that TGF-13 is causally related 
to these various steps merely from its appropriate presence 
in a series of  photomicrographs, the cellular specificity of  the 
localization of TGF-13, particularly at times when critical 
morphogenetic and histogenetic steps occur, strongly argues 
that this might be the case. Furthermore, known biochemical 
actions of TGF-13 also support this view.  Thus, TGF-13 is 
known to have very potent chemotactic (Postlethwaite et al., 
1987), proliferative (Moses et al.,  1985; Centrella et al., 
1987; Hill, et al., 1986; Robey et al., 1987), and differentia- 
tive actions (Ignotz and Massagut,  1986; Seyedin et al., 
1985, 1986; Florini et al., 1986; Massagu6 et al., 1986; O1- 
son et al.,  1986) on various cells of mesenchymal origin. It 
is well known that there is a direct role of extracellular ma- 
trix in promoting and stabilizing specific protein and poly- 
saccharide synthesis during the chain of events involved in 
this entire sequence (Hay,  1981), including the formation of 
somites, the differentiation of somitic mesenchyme to form 
sclerotome, as well as the subsequent chondrification and 
ossification of the sclerotome to form vertebrae. TGF-13 has 
recently been shown to be of major importance in controlling 
the formation and destruction of numerous components of 
the extracellular matrix, including various types of collagen, 
as well as fibronectin and proteoglycans; many of these ac- 
tions appear to be a direct effect on gene expression (for a 
review, see Sporn et al., 1987). In some cells, it also controls 
the levels of receptors for molecules such as fibronectin (Ig- 
notz and Massagu6, 1987; J. McDonald, personal communi- 
cation). In addition to its known action on the fibronectin sys- 
tem, it remains to be determined whether TGF-~ might also 
be a regulator of the synthesis of various other adhesion mol- 
ecules,  such as cytotactin, neural cell adhesion molecule 
(N-CAM), and N-cadherin; these molecules have recently 
been shown to have an important role during somitogenesis 
and the subsequent remodeling of somites (Crossin et al., 
1986; Duband et al.,  1987). Of particular relevance to the 
role of TGF-I] in chondrification and ossification is its known 
ability to induce the cartilaginous phenotype (especially type 
II collagen and cartilage-specific proteoglycans) in embry- 
onic mesenchyme (Seyedin et al., 1985, 1986), as well as its 
proliferative and differentiative actions on osteoblasts (Cen- 
trella et al.,  1987; Robey et al.,  1987). 
The participation of TGF-13 in cartilage and bone forma- 
tion is not limited to the axial skeleton, since intense staining 
is also found in craniofacial mesenchyme of neural crest ori- 
gin, destined to become mandible, maxilla, palate, nose and 
nasal  sinuses,  and other  important craniofacial structures 
(see Figs. 3 A and 5). The morphogenetic role of TGF-I3 in 
these structures of neural crest origin is not understood at 
present, although it should again be noted that extracellu- 
iar matrix proteins, particularly fibronectin (Newgreen and 
Thiery, 1980; Rovasio et al., 1983), may have an important 
permissive role in the migration and subsequent differentia- 
tion of neural crest cells, in that they become craniofacial 
mesenchyme. However, recently it has been emphasized that 
matrix proteins other than fibronectin may also have an im- 
portant role in guiding migration of neural crest cells (Rick- 
mann et al.,  1985). In the case of the neural crest-derived 
mesenchyme that forms the developing palate, it is known 
that these cells are highly sensitive to epidermal growth fac- 
tor (EGF) (Yoneda and Pratt, 1981), a peptide whose recep- 
tor is controlled both by TGF-13 (Assoian et al.,  1984) and 
retinoic acid (Jetten,  1981; Roberts et al.,  1984). 
Although the particular antibody we  have  used  in  this 
study,  directed  against  residues  1-30  of the  TGF-I~I se- 
quence, shows little staining of endothelial cells or smooth 
muscle  cells  of the  developing  vascular system,  there  is 
clearly some role (possibly indirect) of TGF-~ in angiogene- 
sis, in that extensive capillary networks are found in areas 
of remodeling and reorganization where TGF-13 staining is 
associated with the mesenchyme. Furthermore,  there ap- 
pears to be a direct role for TGF-13 in the formation of spe- 
cialized structures in the vascular system, such as the pri- 
mordia  of the  heart  valves,  which  are  derived  from the 
mesenchyme of the endocardial cushion tissue. The endo- 
cardial cushions form in the early heart as massive swellings 
rich in collagen (types I and III), fibronectin, and proteogly- 
cans and serve as prevalvular swellings in the atrioventricu- 
lar canal and truncus arteriosus (Fitzharris and Markwald, 
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endocardial cushion tissue forms a plastic connective tissue 
which is involved in the modeling and remodeling of the 
heart, leading to the partitioning of the atrioventricular canal 
and the formation of the connective tissue framework of the 
cardiac valves. 
Again, as in the case of the skeletal system, the known bio- 
chemistry and  cell  biology of TGF-13 strongly  suggest a 
significant role for TGF-I~ in early angiogenesis and then in 
subsequent development of  cardiovascular structures. Effects 
of TGF-13 on synthesis of matrix proteins and its ability to 
shift the relative activities of proteolytic enzymes and their 
corresponding inhibitors are clearly both involved.  Thus, 
both the rate of growth and the phenotype of capillary en- 
dothelial cells are known to be a function of the type of ex- 
tracellular matrix on which they are cultured (Madri et al., 
1983; Madri and Pratt, 1986), and the relative activities of 
plasminogen activator and plasminogen activator inhibitor 
(PAl)  are important for capillary sprouting and branching 
(Rifkin et al., 1984; Dano et al., 1985). Recently, it has also 
been shown that TGF-I~ has a direct organizational action on 
capillary endothelial cells in vitro, which can lead to their 
formation of tubular structures in three-dimensional colla- 
gen gels (Madri et al., 1988). Finally, it has been shown that 
TGF-13 is a potent regulator of the plasminogen activator sys- 
tem, by inducing transcription of the gene (or by stabilizing 
the mRNA) for type 1 plasminogen activator inhibitor (PAI- 
l, an active site-directed serine protease inhibitor, which can 
irreversibly inactivate plasminogen activator; Laiho et al., 
1986; Lund et al.,  1987). Since plasminogen activator has 
long been implicated in embryonic modeling and remodeling 
steps (Strickland et al., 1976; Dano et al., 1985), particularly 
during angiogenesis (Rifkin et al.,  1984), the induction of 
plasminogen activator inhibitor by TGF-13 would appear to 
provide an important regulatory control on unlimited pro- 
teolysis. Similar considerations regarding proteolytic model- 
ing and remodeling may also be germane to the histogenesis 
and organogenesis of the heart and its septa and valves. 
A third major area in which TGF-fl would appear to play 
an important role is in the differentiation  of specialized struc- 
tures in which there is a known interaction between mesen- 
chyme and adjacent epithelial cells. In this study, we have 
shown two such examples, namely the development of the 
hair follicles on the upper and lower labial surfaces of the 
snout (Fig. 10) and the development of tooth buds (Fig. tl). 
In both situations, intense staining of mesenchyme, as well 
as absence of staining of epithelium, is seen. It is well known 
that embryonic mesenchyme may act in some way to "induce" 
adjacent epithelium to differentiate (Grobstein, 1967; Slack, 
1983), although the simple notion of a mesenchymal inducer 
of differentiation has been refined to include the concept that 
the induced epithelial tissue may already be "predifferen- 
tiated" and that a tissue interaction, catalyzed by some prod- 
uct of mesenchyme, may somehow stabilize or enhance a 
"preinduced" state (see Hay,  1981). 
Although at present we clearly cannot directly implicate 
TGF-13 in such a mechanism, one might speculate that TGF-13, 
produced in underlying mesenchyme, induces the formation 
of another molecule, such as osteonectin/SPARC, which is 
believed to have a definite role in modeling and remodel- 
ing of embryonic tissues (Mason et al., 1986), and which is 
known to be localized in the outer cells of whisker follicles 
(Holland et al., 1987). The recent demonstration that TGF-13 
increases cellular levels of mRNA for osteonectin/SPARC 
provides some credence for such a mechanism (Noda and 
Rodan, 1987). Because a principal function for osteonectin/ 
SPARC is to bind calcium and hydroxyapatite (Engel et al., 
1987; Termine et al., 1981), and because the mRNA for this 
protein is found in abundance in osteoblasts and odontoblasts 
(Holland et al.,  1987), the role of TGF-13 in formation of 
bones and teeth may also be related to an inductive action on 
osteonectin/SPARC. 
Although we have shown an important role for TGF-13 in 
embryogenesis in the present study, it is readily apparent that 
a host of new problems remain to be investigated. These in- 
clude the need to investigate the role of TGF-t3 in earlier em- 
bryos than the ones studied here, the need to study species 
other than the mouse (such as the chick, and even to extend 
these  studies  to  amphibian  embryogenesis),  the  need  to 
localize TGF-13 mRNA formation by in situ hybridization, 
the  need  to  develop  satisfactory antibodies  for  immuno- 
histochemical localization of the other form of TGF-13 (type 
2), and the need to determine specific mediators of TGF-13 
action in specific tissues. We are currently pursuing investi- 
gations in all of these areas. 
Mechanistically, TGF-13 appears to have a unique role in 
controlling the function of many other substances of critical 
significance in embryogenesis, whether they be other peptide 
growth factors, receptors for these peptide growth factors, or 
structural or adhesion molecules of the extraceUular matrix. 
It is clear from the survey of the present study that a wealth 
of new information will be forthcoming on the role of TGF-~ 
in the embryo. It should be noted that many common congen- 
ital anomalies, such as those of craniofacial structures or 
structures derived from endocardial cushions, occur in tis- 
sues in which TGF-13 appears to have a  definite morpho- 
genetic action. Conversely, studies on embryos or utilizing 
embryonic cells may provide further information relating to 
critical mechanistic problems in TGF-13 physiology, particu- 
larly in relation to the problem of what signals, in turn, con- 
trol TGF-{3 itself. In this regard, the recent identification of 
retinoic acid as a morphogen in the embryonic chick limb 
bud (Thaller and Eichele, 1987) is particularly intriguing and 
suggests that there may be a significant relationship between 
the mechanisms of action of retinoic acid and TGF-13 (Sporn 
and Roberts,  1983). 
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